Biaryl ether sulfonamides and their use as therapeutic agents
申请人:XENON PHARMACEUTICALS INC.
公开号:US09365578B2
公开(公告)日:2016-06-14
This invention is directed to biaryl ether sulfonamides, or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS
申请人:Xenon Pharmaceuticals Inc.
公开号:EP2773641B1
公开(公告)日:2017-09-27
US9481677B2
申请人:——
公开号:US9481677B2
公开(公告)日:2016-11-01
[EN] BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS<br/>[FR] BIARYLÉTHERSULFONAMIDES ET LEUR UTILISATION EN TANT QU'AGENTS THÉRAPEUTIQUES
申请人:XENON PHARMACEUTICALS INC
公开号:WO2013064984A1
公开(公告)日:2013-05-10
This invention is directed to biaryl ether sulfonamides, or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.